To inform about the FDA approval of an every-8-week maintenance dosing regimen for lebrikizumab in treating moderate-to-severe atopic dermatitis.
Approach:
Key Findings:
No new safety signals were identified in the 32-week ADjoin every-8-week extension.
No patients discontinued treatment due to adverse events through 32 weeks.
Common adverse reactions included conjunctivitis, injection-site reactions, and herpes zoster.
Interpretation:
Lebrikizumab is a monoclonal antibody targeting interleukin-13, approved for patients whose disease is not adequately controlled with topical therapies.
Limitations:
The safety profile is based on data from the ADjoin trial and may not encompass all patient populations.
Conclusion:
The option for every-8-week maintenance dosing represents a significant development for patients with moderate-to-severe atopic dermatitis.
